Moderna Surpasses Q4 Revenue Expectations Despite Vaccine Hurdles

Moderna reported $678M in fourth-quarter sales, beating Wall Street forecasts, while facing FDA rejection on its flu shot. The company eyes 10% growth in 2026 amid cost cuts and new deals.